-
Mashup Score: 7Navigating Non-Metastatic Castration-Resistant Prostate Cancer Treatment in the PSMA PET Era - Neal Shore - 2 day(s) ago
Zach Klaassen discusses the evolving landscape of non-metastatic castration-resistant prostate cancer (nmCRPC) with Neal Shore. They delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. Dr. Shore reflects on three pivotal trials—SPARTAN, PROSPER, and ARAMIS—that have redefined treatment approaches by demonstrating the efficacy of apalutamide, enzalutamide, and…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5Non-Metastatic CRPC in the Era of PSMA PET Imaging: Challenges and Opportunities - Aaron Berger - 27 day(s) ago
Zach Klaassen and Aaron Berger explore the evolving landscape of non-metastatic castration-resistant prostate cancer (CRPC). Dr. Berger highlights the decreasing frequency of non-metastatic CRPC in clinical settings, attributing this shift to advanced imaging techniques, especially PSMA PET scans, which more accurately detect metastatic stages. He notes that in 2022 and 2023, only about 8% of…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Navigating #nmCRPC treatment in the PSMA PET era. Neal Shore, MD, FACS @CURCMB joins @zklaassen_md @GACancerCenter to discuss this evolving landscape and delve into the significant impact of PSMA PET scans on diagnosing and treating nmCRPC. #WatchNow > https://t.co/OFna6XSY9H https://t.co/K0XdrixQlM